John Nardandrea, MD
Family Medicine · Ocala, FLNPI 1871572016
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,285 of the $8,741 with a category attached, or 60.5%. 28 manufacturers reported payments, led by Eli Lilly at 40.3% of the total. Reporting peaked in 2019 at $4,649 and has fallen 99.7% since, to $16 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $32.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- AstraZeneca$835
- Novo Nordisk$761
- Amarin Pharma, Inc.$523
- Boehringer Ingelheim$514
- AbbVie$383
- plus $2K from 22 others
Across 1,604 payments — averaging $19,216 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$14.8M
- Eisai Inc.$14M
- Genentech, Inc.$530K
- E.r. Squibb & Sons, L.L.C.$492K
- Novo Nordisk AS$472K
- Amgen$314K
- plus $214K from 3 others
What the payments were for
- Consulting fees$2,50029%
- Travel & lodging$92711%
- Food & beverage$5,28560%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $3,522 |
| AstraZeneca | 41 | $835 |
| Novo Nordisk | 39 | $761 |
| Amarin Pharma, Inc. | 29 | $523 |
| Boehringer Ingelheim | 27 | $514 |
| AbbVie(2 entities) | 20 | $383 |
| GSK | 20 | $368 |
| Lilly USA, LLC | 17 | $342 |
| Amgen(2 entities) | 18 | $305 |
| Johnson & Johnson | 9 | $227 |
| Pfizer | 11 | $201 |
| Astellas Pharma US Inc | 7 | $153 |
| Merck | 9 | $149 |
| Medtronic | 1 | $118 |
| Bayer | 1 | $82 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Eisai Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Novartis | 1 | $19 |
| CMP Pharma, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Abbott | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$118
- SPRAVATO$112
How this compares
$8,741 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $86,551 |
| OzempicSemaglutide | 39 | $40,292 |
| FarxigaDapagliflozin Propanediol | 28 | $37,604 |
| EliquisApixaban | 41 | $35,597 |
| MounjaroTirzepatide | 32 | $33,014 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $30,371 |
| Repatha SureclickEvolocumab | 23 | $27,089 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $21,158 |
| InvokanaCanagliflozin | 17 | $14,246 |
| JanuviaSitagliptin Phosphate | 11 | $13,637 |
| PremarinEstrogens, Conjugated | 17 | $5,707 |
| Rosuvastatin Calcium | 617 | $5,437 |
| Amlodipine Besylate | 527 | $3,800 |
| Atorvastatin Calcium | 377 | $3,782 |
| Gabapentin | 176 | $3,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $514 | $86,55156 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $368 | $51,52951 claims |
| PfizerEliquis, Premarin, Paxlovid | $201 | $42,73470 claims |
| Novo NordiskOzempic | $761 | $40,29239 claims |
| AstraZenecaFarxiga | $835 | $37,60428 claims |
| Lilly USA, LLCMounjaro | $342 | $33,01432 claims |
| Johnson & JohnsonInvokana | $227 | $14,24617 claims |
| MerckJanuvia | $149 | $13,63711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ocala
- Sidney ClevingerOcala$110K
- Lorn MillerOcala$53K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.